ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "registry and rheumatoid arthritis (RA)"

  • Abstract Number: 2813 • 2014 ACR/ARHP Annual Meeting

    Correlation of Morning Stiffness with Measures of Higher Disease Activity in a Large US Registry Population of Rheumatoid Arthritis Patients

    Vibeke Strand1, Robert J. Holt2, Katherine C. Saunders3, Jeffery D. Kent4, Ping Xu5, Amy Y. Grahn4, Marc Mason3 and Carol J. Etzel6,7, 1Stanford University, Palo Alto, CA, 2University of Illinois - Chicago, Chicago, IL, 3Corrona, LLC., Southborough, MA, 4Horizon Pharma, Inc., Deerfield, IL, 5Axio Research LLC, Seattle, WA, 6PO Box 786, Corrona, LLC., Southborough, MA, 7Department of Epidemiology, UT MD Anderson, Houston, TX

    Background/Purpose : Morning stiffness may not be specifically queried by rheumatologists in the course of their regular interactions with rheumatoid arthritis (RA) patients.  This analysis…
  • Abstract Number: 2562 • 2014 ACR/ARHP Annual Meeting

    The Comparative One-Year Drug Survival Rate of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid arthritis  and ankylosing spondylitis; results from Turkbio Registry

    Ismail Sari1, Umut Kalyoncu2, Ahmet Mesut Onat3, Omer Nuri Pamuk4, Omer Karadag2, Bunyamin Kisacik3, Niels Steen Krogh5, Soner Şenel6, Fatih Saritaş7, Ihsan Ertenli2, Sedat Kiraz2, Pinar Cetin1, Fatos Onen1 and Nurullah Akkoc1, 1Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, 2Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey, 3Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, 4Department of Rheumatology, Trakya University School of Medicine, Edirne, Turkey, 5Consultant, ZiteLab Aps, Copenhagen, Denmark, 6Rheumatology, Erciyes University School of Medicine, Kayseri, Turkey, 7Rheumatology, Trakya University School of Medicine, Edirne, Turkey

    Background/Purpose Three different anti–tumor necrosis factor α (anti-TNFα) drugs (infliximab, etanercept, and adalimumab) are approved for patients with rheumatoid arthritis (RA) and particular ankylosing spondylitis…
  • Abstract Number: 2504 • 2014 ACR/ARHP Annual Meeting

    Impact of Concomitant Methotrexate on the Enhanced Clinical Efficacy of Abatacept after 24 Weeks in Rheumatoid Arthritis Patients

    Nobunori Takahashi1, Toshihisa Kojima1, Yuji Hirano2, Yasuhide Kanayama3, Koji Funahashi4 and Naoki Ishiguro1, 1Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 2Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, 3Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, 4Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Background/Purpose Abatacept (ABT), a selective co-stimulation modulator, is the first in a new class of biologic agents for the treatment of rheumatoid arthritis (RA) that…
  • Abstract Number: 2416 • 2014 ACR/ARHP Annual Meeting

    Do Patterns of Joint Swelling or Tenderness in Rheumatoid Arthritis Patients Impact Disease Activity Outcomes and Pain?  Implications for Clinical Practice

    Regan Arendse1, John Kelsall2, J. Antonio Avina-Zubieta3, Philip Baer4, Erica Weinberg4, Jude Rodrigues5, Algis Jovaisas6, Isabelle Fortin7, Maqbool Sheriff8, Majed M. Khraishi9, Emmanouil Rampakakis10, John S. Sampalis10, Francois Nantel11, Susan Otawa12 and Allen J Lehman12, 1University of Saskatchewan, Saskatoon, SK, Canada, 2The Mary Pack Arthritis Centre, Vancouver, BC, Canada, 3Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, 4Private Practice, Scarborough, ON, Canada, 5Clinical Research and Arthritis Centre, Windsor, ON, Canada, 6194 Main Street, University of Ottawa, Ottawa, ON, Canada, 7Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, 8Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 9Nexus Clinical Research, Memorial University of Newfoundland, St Johns, NF, Canada, 10JSS Medical Research, Montreal, QC, Canada, 11Janssen Inc., Toronto, ON, Canada, 12Medical Affairs, Janssen Inc., Toronto, ON, Canada

    Background/Purpose This analysis aimed to describe the pattern of specific joint involvement (tender and/or swollen) pre- and post-TNFi treatment and the impact of specific joint…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology